Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Day (June 2019)
19 slides from Qiagen's investor day presentation, Jun 19, 2019
Slide 1: 2019 Analyst & Investor Day: Bioinformatics
2019 Analyst & Investor Day Bioinformatics Building the best suite of content-driven analytics Jonathan Sheldon Senior Vice President, Head of Bioinformatics Business Area Sample to Insight
Slide 2: Disclaimer
Disclaimer Safe Harbor Statement: This presentation contains both historical and forward-looking Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate statements. All statements other than statements of historical fact are, or may be deemed to be (CER) basis,
Slide 3: Bioinformatics market offers dynamic growth opportunities
Bioinformatics market offers dynamic growth opportunities Our customers Total addressable market Key trends • Bioinformatics industry transition Clinical testing Evolution of regulatory landscape accelerating entry into the mainstream of healthcare IT Decision support for QIAGEN market share: ~20% •
Slide 4: Building the best suite of content-driven analytics
Building the best suite of content-driven analytics Bioinformatics sales trends(1) Discovery informatics Curated research data and knowledge bases with #1 2019-2023 target: integrated analysis and interpretation solutions ~+10-15% CER CAGR 2012-2018: ~+10-15% CER CAGR ~$65 m ~$48 m Clinical testing
Slide 5: Strategy: Expand leadership in data analysis, interpretation and content
Strategy: Expand leadership in data analysis, interpretation and content Build on genomics leadership Help customers achieve fast and actionable insights The partner of Expand our datasets choice to get Combine our curated and public data with secure access to patient datasets actionable insights fr
Slide 6: QIAGEN is the partner of choice for actionable insights from molecular and real world data
QIAGEN is the partner of choice for actionable insights from molecular and real world data Curated literature Guidelines Protocols Patient data Drug labels Ontology + Models Curated Big Data Genomic datasets Sample to Insight 2019 Analyst & Investor Day 6
Slide 7: Build on genomics leadership: Help customers achieve fast and actionable insights
Build on genomics leadership: Help customers achieve fast and actionable insights 2019 2016 Sample to Insight 2019 Analyst & Investor Day 7
Slide 8: Case study: One QIAGEN order to receive complete Sample to Insight NGS solution
Case study: One QIAGEN order to receive complete Sample to Insight NGS solution QIAseq DNA Panels CLC Genomics QCI-Interpret and Index Kit Workbench BIOLOGICAL VALUABLE SAMPLE MOLECULAR INSIGHTS Easy to buy Superior analysis results Powerful and easy to use integrated solution *Products are intended
Slide 9: Case study: QIAGEN Clinical Insight (QCI) as preferred partner for national programs
Case study: QIAGEN Clinical Insight (QCI) as preferred partner for national programs Multi-year partnership as preferred vendor Multi-year partnership to deliver custom Multi-year partnership for molecular oncology for Genomics England to analyze 5 million NGS patient data interpretation for genetic
Slide 10: Expand our datasets: Combine our curated and public data with patient datasets
Expand our datasets: Combine our curated and public data with patient datasets Curated literature Guidelines Protocols Patient data Drug labels Ontology + Models Curated Big Data Genomic datasets Sample to Insight 2019 Analyst & Investor Day 10
Slide 11: Expand QIAGEN datasets with unique industrial-scale expert Knowledge Base curation
Expand QIAGEN datasets with unique industrial-scale expert Knowledge Base curation A “factory process” for very large scale, systematic clinical and scientific knowledge curation High quality High volume Comprehensive Proven quality Cost-effective QIAGEN Knowledge Base Huge collection of sci
Slide 12: QIAGEN Clinical Insight (QCI) setting standards as resource for clinical decision support
QIAGEN Clinical Insight (QCI) setting standards as resource for clinical decision support Cardio- Somatic Inherited Rare Pharmaco- vascular diseases diseases diseases genetics diseases QIAGEN Knowledge Base QIAGEN Clinical Insight (QCI) Customer Access to >40 scientific and clinical Ingenuity N-of-O
Slide 13: Case study: N-of-One strengthens clinical decision support with real-world evidence
Case study: N-of-One strengthens clinical decision support with real-world evidence Molecular oncology decision support MarkerMine Pioneer in molecular oncology decision support services Anonymous patient molecular profiles Well recognized services provider for patient treatment infomation and clini
Slide 14: Enhanced data mining: Discover new connections in data to support better outcomes
Enhanced data mining: Discover new connections in data to support better outcomes Curated literature Guidelines Protocols Patient data Drug labels Ontology + Models Curated Big Data Genomic datasets Sample to Insight 2019 Analyst & Investor Day 14
Slide 15: Case study: Analysis Match catalyzes value for customers with dive into comparative data
Case study: Analysis Match catalyzes value for customers with dive into comparative data >500,000 public ‘OMIC datasets Journal articles Clinical trials Experiment curation Knowledge curation and quality assurance and quality assurance Processed datasets OncoLand and DiseaseLand Key advantages of An
Slide 16: QIAGEN is the partner of choice for actionable insights from complex molecular and real world data
QIAGEN is the partner of choice for actionable insights from complex molecular and real world data Curated literature Guidelines Protocols Patient data Drug labels Ontology + Models Curated Big Data Genomic datasets Sample to Insight 2019 Analyst & Investor Day 16
Slide 17: N-of-One helps power QCI, providing access to new markets and customer segments
N-of-One helps power QCI, providing access to new markets and customer segments QIAGEN Clinical Insight Portfolio Example QCI report Clinical labs Pharma and Biotech Payers Analyze PrecisionInsights™ Genomic Insights™ Genomic Insights™ Interpret RapidInsights™ On-demand curation Analytical services
Slide 18: Case study: Genomic real-world evidence to optimize drug development and CDx usage
Case study: Genomic real-world evidence to optimize drug development and CDx usage Basic Pre-clinical Phase I Phase II Phase III Launch Phase IV research studies Protocol design Site selection Patient recruitment Ingenuity QIAGEN Clinical Insight Pathway Optimal for launch and Phase IV Analysis Pati
Slide 19: Summary
Summary • Transforming from tools/tech vendor to delivering real-world healthcare insights • Offering unique integrated data assets combined with deep analytical skills • Creating scale and core enterprise software capabilities • Supporting customers to realize complete value of genomic data Sample